Profil
Lisa Amaya Price is currently Chief Human Resources Officer at Disc Medicine, Inc. since 2026.
Formerly, Ms. Price was Chief Human Resources Officer & Senior VP at Deciphera Pharmaceuticals, Inc. from 2022 to 2026 and Chief People Officer at LGC Group, Inc. Education includes graduate studies at Simmons University, undergraduate studies at Bard College, and an MBA from F.W.
Olin Graduate School of Business.
Aktive Positionen von Lisa Amaya Price
| Unternehmen | Position | Beginn |
|---|---|---|
| DISC MEDICINE, INC. | Personalreferent | 12.01.2026 |
Ehemalige bekannte Positionen von Lisa Amaya Price
| Unternehmen | Position | Ende |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Personalreferent | 01.01.2026 |
LGC Group, Inc.
LGC Group, Inc. Medical SpecialtiesHealth Technology Develops life science tools, components and solutions | Personalreferent | - |
Ausbildung von Lisa Amaya Price
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Simmons University
Simmons University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bard College
Bard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F.W. Olin Graduate School of Business
F.W. Olin Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
LGC Group, Inc.
LGC Group, Inc. Medical SpecialtiesHealth Technology Develops life science tools, components and solutions | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
















